This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Study Shows Nanosphere Verisens(TM) CTnI Ultra-Sensitive Troponin I Assay Predicts Heart Failure Deterioration

NORTHBROOK, Ill., Dec. 17, 2010 (GLOBE NEWSWIRE) -- A clinical study released online by the European Journal of Heart Failure, a publication of the European Society of Cardiology, demonstrates the value of using Nanosphere's (Nasdaq:NSPH) Verisens™ cTnI assay (RUO) to detect very low levels of troponin I in hospitalized patients with heart failure.*

The research, conducted at the Veterans Affairs (VA) Hospital in San Diego, was part of the "Veterans Affairs Effects of Therapy" study. In addition to the VA, there were investigators from UCSD and the Cleveland Clinic. The study employing the Verisens™ assay for troponin I involved 144 patients discharged with acute heart failure, who were followed for 90 days. 

Both the BNP and the Verisens™ cTnI assay were tested on blood drawn at admission, discharge, and up to four consecutive days while hospitalized. The new Verisens™ cTnI assay could quantitatively measure troponin I in more than 99% of blood samples. Even at low concentrations, troponin I in the higher quartiles identified increased risk of death and re-hospitalization for patients. Additionally, patients who had rising levels at any concentration while treated in the hospital, had a higher risk of death. Of further note, these results were statistically significant for the Verisens™ cTnI assay, but not for BNP.

"These results are already proving the value of the Nanosphere Verisens™ technology's unmatched sensitivity to measure protein biomarkers, such as low levels of troponin I in heart failure patients," emphasized Winton Gibbons, Senior Vice President of Business Development at Nanosphere.

Additionally, Dr. Alan Maisel, an investigator on the study and well-know expert in biomarkers for heart failure comments that, "We have proven serial sampling of high sensitivity troponin levels in patients admitted for acute heart failure will accomplish two things. First, it will help rule out occlusion of a coronary artery (low levels of troponin) as a cause for decompensation.  Secondly, it will help risk stratify patients.  Eventually this will allow us to use these high-sensitive levels to target with newer 'anti-ischemic' drugs."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs